Consensus statement from 2nd International Conference on Controversies in Vitamin D
Andrea Giustina,Robert A. Adler,Neil Binkley,Jens Bollerslev,Jens Bollerslev,Roger Bouillon,Bess Dawson-Hughes,Peter R. Ebeling,David Feldman,Anna Maria Formenti,Marise Lazaretti-Castro,Claudio Marcocci,René Rizzoli,Christopher T. Sempos,J. P. Bilezikian +14 more
Reads0
Chats0
TLDR
The 2nd International Conference on Controversies in Vitamin D was held in Monteriggioni (Siena), Italy, September 11-14, 2018 to address ongoing controversies and timely topics in vitamin D research, to review available data related to these topics and controversies and to suggest a research agenda to clarify areas of uncertainty.Abstract:
The 2nd International Conference on Controversies in Vitamin D was held in Monteriggioni (Siena), Italy, September 11-14, 2018. The aim of this meeting was to address ongoing controversies and timely topics in vitamin D research, to review available data related to these topics and controversies, to promote discussion to help resolve lingering issues and ultimately to suggest a research agenda to clarify areas of uncertainty. Several issues from the first conference, held in 2017, were revisited, such as assays used to determine serum 25-hydroxyvitamin D [25(OH)D] concentration, which remains a critical and controversial issue for defining vitamin D status. Definitions of vitamin D nutritional status (i.e. sufficiency, insufficiency and deficiency) were also revisited. New areas were reviewed, including vitamin D threshold values and how they should be defined in the context of specific diseases, sources of vitamin D and risk factors associated with vitamin D deficiency. Non-skeletal aspects related to vitamin D were also discussed, including the reproductive system, neurology, chronic kidney disease and falls. The therapeutic role of vitamin D and findings from recent clinical trials were also addressed. The topics were considered by 3 focus groups and divided into three main areas: 1) "Laboratory": assays and threshold values to define vitamin D status; 2) "Clinical": sources of vitamin D and risk factors and role of vitamin D in non-skeletal disease and 3) "Therapeutics": controversial issues on observational studies and recent randomized controlled trials. In this report, we present a summary of our findings.read more
Citations
More filters
Executive summary of the 2017 KDIGO Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) Guideline Update: what’s changed and why it matters
Markus Ketteler,Geoffrey A. Block,Pieter Evenepoel,Masafumi Fukagawa,Charles A. Herzog,Linda M. McCann,Sharon M. Moe,Sharon M. Moe,Rukshana Shroff,Marcello Tonelli,Nigel D Toussaint,Marc G. Vervloet,Mary B. Leonard +12 more
TL;DR: This review highlights key aspects of the 2017 CKD-MBD Guideline Update, with an emphasis on the rationale for the changes made to the original guideline document.
Journal ArticleDOI
Vitamin D and marine omega 3 fatty acid supplementation and incident autoimmune disease: VITAL randomized controlled trial
Jill Hahn,Nancy R. Cook,Erik K. Alexander,Sonia Friedman,Joseph Walter,Vadim Bubes,Gregory Kotler,I-min M Lee,JoAnn E. Manson,Karen H. Costenbader +9 more
TL;DR: The VITAL trial as discussed by the authors investigated whether vitamin D and marine derived long chain omega 3 fatty acids reduce autoimmune disease risk and found that omega 3 supplements with or without vitamin D reduced the autoimmune disease rate by 15% (not statistically significant).
Journal ArticleDOI
Endocrine and metabolic aspects of the COVID-19 pandemic.
TL;DR: Endocrine treatment modifications as a consequence of COVID-19 infection are required in a proactive manner, in order to avoid decompensation and eventual hospital admission in patients with diabetes and adrenal insufficiency.
References
More filters
Journal ArticleDOI
The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials
Julian P T Higgins,Douglas G. Altman,Peter C Gøtzsche,Peter Jüni,David Moher,Andrew D Oxman,Jelena Savović,Kenneth F. Schulz,Laura Weeks,Jonathan A C Sterne +9 more
TL;DR: The Cochrane Collaboration’s tool for assessing risk of bias aims to make the process clearer and more accurate.
Journal ArticleDOI
Evaluation, Treatment, and Prevention of Vitamin D Deficiency: an Endocrine Society Clinical Practice Guideline
Michael F. Holick,Neil Binkley,Heike A. Bischoff-Ferrari,Catherine M. Gordon,David A. Hanley,Robert P. Heaney,M. Hassan Murad,Connie M. Weaver +7 more
TL;DR: Considering that vitamin D deficiency is very common in all age groups and that few foods contain vitamin D, the Task Force recommended supplementation at suggested daily intake and tolerable upper limit levels, depending on age and clinical circumstances.
Journal Article
Evaluation, treatment, and prevention of vitamin D deficiency: An endocrine society clinical practice guideline (Journal of Clinical Endocrinology and Metabolism (2011) 96, (1911-1930))
Michael F. Holick,Neil Binkley,Heike A. Bischoff-Ferrari,Catherine M. Gordon,David A. Hanley,Robert P. Heaney,M. Hassan Murad,Connie M. Weaver +7 more
TL;DR: The Task Force as discussed by the authors provided guidelines to clinicians for the evaluation, treatment, and prevention of vitamin D deficiency with an emphasis on the care of patients who are at risk for deficiency, based on systematic reviews of evidence and discussions during several conference calls and e-mail communications.
Journal ArticleDOI
The 2011 Report on Dietary Reference Intakes for Calcium and Vitamin D from the Institute of Medicine: What Clinicians Need to Know
A. Catharine Ross,JoAnn E. Manson,Steven A. Abrams,John F. Aloia,John F. Aloia,Patsy M. Brannon,Steven K. Clinton,Ramon Durazo-Arvizu,J. Christopher Gallagher,Richard L. Gallo,Glenville Jones,Christopher S. Kovacs,Susan Taylor Mayne,Clifford J. Rosen,Sue A. Shapses +14 more
TL;DR: The Committee concluded that the prevalence of vitamin D inadequacy in North America has been overestimated and urgent research and clinical priorities were identified, including reassessment of laboratory ranges for 25-hydroxyvitamin D, to avoid problems of both undertreatment and overtreatment.
Journal ArticleDOI
Fetal origins of coronary heart disease
TL;DR: The fetal origins hypothesis states that fetal undernutrition in middle to late gestation, which leads to disproportionate fetal growth, programmes later coronary heart disease.
Related Papers (5)
Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data
Adrian R. Martineau,David A. Jolliffe,Richard Hooper,Lauren Greenberg,John F. Aloia,Peter Bergman,Gal Dubnov-Raz,Susanna Esposito,Davaasambuu Ganmaa,Adit A. Ginde,Emma C Goodall,Cameron C. Grant,Chris Griffiths,Wim Janssens,Ilkka Laaksi,Semira Manaseki-Holland,David T. Mauger,David R. Murdoch,Rachel E. Neale,Judy R. Rees,Steve Simpson,Iwona Stelmach,Geeta Trilok Kumar,Mitsuyoshi Urashima,Carlos A. Camargo +24 more